http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Virios Therapeutics Announces Second Quarter 2024 Financial Results
-
Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
-
Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
-
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
-
Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
-
Virios Therapeutics (VIRI) Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
-
Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
-
Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
-
Virios Therapeutics (VIRI) Issues Shareholder Letter
-
Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
-
Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
-
Virios Therapeutics (VIRI) Reaches Alignment with FDA on Requirements for Advancing IMC-2 for Long-COVID
-
Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
-
Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
-
Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
-
Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
-
Virios Therapeutics (VIRI) Announces Termination of At-The-Market Sales Agreement
-
Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
-
Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
-
Virios Therapeutics (VIRI) Halts At-The-Market Offering Sales
-
Virios Therapeutics Announces Halt to At-The-Market Offering Sales
-
Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
-
Virios Therapeutics (VIRI) to Advance IMC-1 to Phase 3 Development
-
Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
-
Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
-
Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Labe
-
Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia
-
Virios Therapeutics Announces First Quarter 2023 Financial Results
-
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
-
Virios Therapeutics (VIRI) Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program
-
Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia
-
Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
-
Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023
-
Virios Therapeutics (VIRI) Announces Exploratory Long-COVID Trial Top-Line Data Projected in June 2023
-
Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023
-
Virios Therapeutics (VIRI) Scheduled FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program
-
Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program
-
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase
-
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
-
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022
-
Virios Therapeutics (VIRI) Phase 2b Study of IMC-1 in Fibromyalgia Did Not Achieve Statistical Significance
-
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia
-
Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
-
Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
-
Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
-
Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
-
Virios Therapeutics (VIRI) Featured in Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders
-
Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patien
